LOG IN
SIGN UP
MARKET
AFMD
AFMD
Affimed
NASDAQ
Real-time Quotes | Nasdaq Last Sale
2.810
+0.040
+1.44%
After Hours: 2.810 0 0.00% 16:02 07/01 EDT
OPEN
2.790
PREV CLOSE
2.770
HIGH
2.860
LOW
2.730
VOLUME
448.29K
TURNOVER
0
52 WEEK HIGH
7.99
52 WEEK LOW
2.230
MARKET CAP
410.03M
P/E (TTM)
-4.0748
1D
5D
1M
3M
1Y
5Y
BRIEF-Affimed Establishes Scientific Advisory Board
BRIEF-Affimed Establishes Scientific Advisory Board
Reuters · 1d ago
Affimed Establishes Scientific Advisory Board
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncologyScientific Advisory Board to provide guidance on the Company’s development strategy across assets and asses...
GlobeNewswire · 1d ago
--SVB Securities Adjusts Affimed Price Target to $9 From $10, Maintains Outperform Rating
MT Newswires · 06/23 13:33
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic...
GlobeNewswire · 06/10 14:31
Affimed Says Innate Cell Engager Induces Effective Anti-Tumor Activity in Preclinical Study
MT Newswires · 06/10 12:05
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows.
Benzinga · 06/09 17:21
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 06/01 11:55
BRIEF-Affimed Reports Q1 Loss Per Share of 0.14 Euros
reuters.com · 06/01 11:50
No Data
Learn about the latest financial forecast of AFMD. Analyze the recent business situations of Affimed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 9 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AFMD stock price target is 11.69 with a high estimate of 17.77 and a low estimate of 6.91.
Current 2.810
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Institutional Holdings
Institutions: 147
Institutional Holdings: 88.26M
% Owned: 60.48%
Shares Outstanding: 145.92M
TypeInstitutionsShares
Increased
32
4.74M
New
14
1.73M
Decreased
46
7.90M
Sold Out
18
726.52K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman - Supervisory/Independent Director
Thomas Hecht
Chief Executive Officer/Management Board
Adi Hoess
Chief Financial Officer/Management Board
Angus Smith
Chief Operating Officer/Management Board
Wolfgang Fischer
Chief Scientific Officer/Management Board
Arndt Schottelius
Management Board
Andreas Harstrick
Management Board
Denise Mueller
Independent Director/Supervisory Board
Bernhard Ehmer
Independent Director/Supervisory Board
Ulrich Grau
Independent Director/Supervisory Board
Uta Kemmerich-Keil
Independent Director/Supervisory Board
Mathieu Simon
Independent Director/Supervisory Board
Harry Welten
Supervisory Board
Annalisa Jenkins
No Data
No Data
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.